← Back
Oncology

Telisotuzumab vedotin (Teliso-V)

AbbVie

c-Met directed ADC. LUMINOSITY Phase 2 and TeliMET Phase 3 trials in EGFR-wild type NSCLC.

NSCLCc-Met overexpression

Linked Studies

NCT03539536PrimaryACTIVE_NOT_RECRUITINGPHASE2

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung CancerUpdated Nov 2025
Loading comments…

Also Known As

Other names

telisotuzumab
Search all trials →Request coverage update